Genmab A/S (NASDAQ:GMAB - Free Report) - Analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of Genmab A/S in a research report issued on Wednesday, April 3rd. William Blair analyst M. Phipps now forecasts that the company will earn $1.07 per share for the year, down from their prior estimate of $1.44. The consensus estimate for Genmab A/S's current full-year earnings is $1.07 per share. William Blair also issued estimates for Genmab A/S's FY2026 earnings at $1.60 EPS and FY2027 earnings at $2.16 EPS.
Other equities research analysts have also recently issued research reports about the company. Citigroup cut Genmab A/S from a "neutral" rating to a "sell" rating in a report on Monday, January 22nd. BMO Capital Markets raised Genmab A/S from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $46.00 to $48.00 in a research report on Friday, February 23rd. Morgan Stanley reaffirmed an "underweight" rating on shares of Genmab A/S in a research report on Tuesday, March 26th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Thursday. Finally, Truist Financial reaffirmed a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Tuesday, March 26th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Genmab A/S presently has an average rating of "Hold" and a consensus price target of $48.50.
Get Our Latest Stock Analysis on Genmab A/S
Genmab A/S Stock Up 0.3 %
Shares of GMAB stock traded up $0.10 during mid-day trading on Monday, hitting $29.86. 222,156 shares of the company's stock were exchanged, compared to its average volume of 620,656. Genmab A/S has a fifty-two week low of $26.32 and a fifty-two week high of $42.99. The stock has a 50-day simple moving average of $29.13 and a two-hundred day simple moving average of $30.63. The stock has a market cap of $19.73 billion, a price-to-earnings ratio of 31.10, a PEG ratio of 2.12 and a beta of 0.98.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.02. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The business had revenue of $675.29 million for the quarter, compared to analysts' expectations of $678.14 million.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. First Manhattan Co. purchased a new stake in shares of Genmab A/S during the fourth quarter worth about $26,000. Headlands Technologies LLC purchased a new stake in shares of Genmab A/S during the third quarter worth about $27,000. Pinnacle Bancorp Inc. increased its position in shares of Genmab A/S by 315.8% during the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company's stock worth $27,000 after acquiring an additional 638 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Genmab A/S by 194.0% during the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company's stock worth $34,000 after acquiring an additional 749 shares during the last quarter. Finally, NBC Securities Inc. purchased a new stake in shares of Genmab A/S during the third quarter worth about $37,000. 7.07% of the stock is owned by hedge funds and other institutional investors.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
